A. Jeannin, J. Salem, C. Vemeer, C. Amouyal, and O. Bourron,

, Writing -original draft: Anne-Caroline Jeannin

:. Writing--review-&-editing, Z. Salem, F. Massy, and . Phan, Marine Halbron, Christian Funck-Brentano, Agnès Hartemann, Olivier Bourron. case of Keutel syndrome, J Thromb Haemost, vol.9, issue.6, p.21435166, 2011.

S. Mertsch, L. J. Schurgers, K. Weber, W. Paulus, and V. Senner, Matrix gla protein (MGP): an overexpressed and migration-promoting mesenchymal component in glioblastoma. BMC Cancer, vol.9, p.302, 2009.

I. Santa-maria, J. Avila, and A. Rabano, Differential gene expression analysis of human entorhinal cortex support a possible role of some extracellular matrix proteins in the onset of Alzheimer disease, Neurosci Lett, vol.468, issue.3, pp.225-233, 2010.

O. Bourron, C. E. Aubert, S. Liabeuf, P. Cluzel, F. Lajat-kiss et al., Below-knee arterial calcification in type 2 diabetes: association with receptor activator of nuclear factor kappaB ligand, osteoprotegerin, and neuropathy, J Clin Endocrinol Metab, vol.99, issue.11, pp.4250-4258, 2014.

M. J. Young, A. J. Boulton, A. F. Macleod, D. R. Williams, and P. H. Sonksen, A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population, Diabetologia, vol.36, issue.2, pp.150-154, 1993.

C. A. Abbott, A. L. Carrington, H. Ashe, S. Bath, L. C. Every et al., The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort, Diabet Med, vol.19, issue.5, p.12027925, 2002.

M. T. Gadia, N. Natori, L. B. Ramos, D. R. Ayyar, J. S. Skyler et al., Influence of height on quantitative sensory, nerve-conduction, and clinical indices of diabetic peripheral neuropathy. Diabetes Care, 1987.

, , vol.10, pp.613-619

C. W. Grote and D. E. Wright, A Role for Insulin in Diabetic Neuropathy, Front Neurosci, vol.10, p.581, 2016.

A. F. Zebboudj, M. Imura, and K. Bostrom, Matrix GLA protein, a regulatory protein for bone morphogenetic protein-2, J Biol Chem, vol.277, issue.6, pp.4388-94, 2002.

J. I. Moon and S. J. Birren, Target-dependent inhibition of sympathetic neuron growth via modulation of a BMP signaling pathway, Dev Biol, vol.315, issue.2, pp.404-421, 2008.

A. Majdazari, J. Stubbusch, C. M. Muller, M. Hennchen, M. Weber et al., Dendrite complexity of sympathetic neurons is controlled during postnatal development by BMP signaling, J Neurosci, vol.33, issue.38, pp.15132-15176, 2013.

J. J. Dore, K. L. Crotty, and S. J. Birren, Inhibition of glial maturation by bone morphogenetic protein 2 in a neural crest-derived cell line, Dev Neurosci, vol.27, issue.1, pp.37-48, 2005.

Y. L. Wang, D. Z. Wang, X. Nie, D. L. Lei, Y. P. Liu et al., The role of bone morphogenetic protein-2 in vivo in regeneration of peripheral nerves, Br J Oral Maxillofac Surg, vol.45, issue.3, pp.197-202, 2007.

F. Gonzalez-perez, E. Udina, and X. Navarro, Extracellular matrix components in peripheral nerve regeneration, Int Rev Neurobiol, vol.108, p.24083438, 2013.

S. K. Nishimoto and M. Nishimoto, Matrix Gla protein C-terminal region binds to vitronectin. Co-localization suggests binding occurs during tissue development, Matrix Biol, vol.24, issue.5, pp.353-61, 2005.

S. K. Nishimoto and M. Nishimoto, Matrix gla protein binds to fibronectin and enhances cell attachment and spreading on fibronectin, Int J Cell Biol, p.807013, 2014.

E. C. Cranenburg, R. Koos, L. J. Schurgers, E. J. Magdeleyns, T. H. Schoonbrood et al., Characterisation and potential diagnostic value of circulating matrix Gla protein (MGP) species. Thromb Haemost, vol.104, pp.811-833, 2010.

G. W. Dalmeijer, Y. T. Van-der-schouw, E. J. Magdeleyns, C. Vermeer, W. M. Verschuren et al., Matrix Gla protein species and risk of cardiovascular events in type 2 diabetic patients. Diabetes Care, vol.36, p.23877986, 2013.

J. G. Hall, R. M. Pauli, and K. M. Wilson, Maternal and fetal sequelae of anticoagulation during pregnancy, Am J Med, vol.68, issue.1, pp.90181-90184, 1980.

D. C. Popescu, H. Huang, N. K. Singhal, L. Shriver, J. Mcdonough et al., Vitamin K enhances the production of brain sulfatides during remyelination, PLoS One, vol.13, issue.8, p.203057, 2018.

T. Coetzee, N. Fujita, J. Dupree, R. Shi, A. Blight et al., Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability, Cell, vol.86, issue.2, pp.209-228, 1996.

M. Nakajima, S. Furukawa, K. Hayashi, A. Yamada, T. Kawashima et al., Age-dependent survivalpromoting activity of vitamin K on cultured CNS neurons, Brain Res Dev Brain Res, vol.73, issue.1, pp.90041-90049, 1993.

C. Druet, I. Bourdel-marchasson, A. Weill, E. Eschwege, A. Penfornis et al., Type 2 diabetes in France: epidemiology, trends of medical care

, Presse Med, vol.42, issue.5, pp.830-838, 2013.

T. Zhu, Q. Meng, J. J. Lou, X. Zhang, and L. , Toll-like receptor 4 and tumor necrosis factor-alpha as diagnostic biomarkers for diabetic peripheral neuropathy, Neurosci Lett, vol.585, pp.28-32, 2015.

J. Li, H. Zhang, M. Xie, L. Yan, J. Chen et al., NSE, a potential biomarker, is closely connected to diabetic peripheral neuropathy. Diabetes Care, vol.36, pp.3405-3415, 2013.

S. Roumeliotis, E. Dounousi, T. Eleftheriadis, and V. Liakopoulos, Association of the Inactive Circulating Matrix Gla Protein with Vitamin K Intake, Calcification, Mortality, and Cardiovascular Disease: A Review, Int J Mol Sci, vol.20, issue.3, 2019.

H. Puzantian, S. R. Akers, G. Oldland, K. Javaid, R. Miller et al., Circulating Dephospho-Uncarboxylated Matrix Gla-Protein Is Associated With Kidney Dysfunction and Arterial Stiffness, Am J Hypertens, vol.31, issue.9, pp.988-94, 2018.

I. Kurnatowska, P. Grzelak, A. Masajtis-zagajewska, M. Kaczmarska, L. Stefanczyk et al., Plasma Desphospho-Uncarboxylated Matrix Gla Protein as a Marker of Kidney Damage and Cardiovascular Risk in Advanced Stage of Chronic Kidney Disease, Kidney Blood Press Res, vol.41, issue.3, pp.231-240, 2016.

F. F. Wei, Q. F. Huang, Z. Y. Zhang, V. Keer, K. Thijs et al., Inactive matrix Gla protein is a novel circulating biomarker predicting retinal arteriolar narrowing in humans, Sci Rep, vol.8, issue.1, p.30305657, 2018.

C. Chalk, T. J. Benstead, and F. Moore, Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev, vol.17, p.4572, 2007.

A. I. Vinik, V. Bril, P. Kempler, W. J. Litchy, S. Tesfaye et al., Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial, Clin Ther, vol.27, issue.8, pp.1164-80, 2005.

P. J. Thornalley, Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts, Arch Biochem Biophys, vol.419, issue.1, pp.31-40, 2003.

N. Papanas and D. Ziegler, Efficacy of alpha-lipoic acid in diabetic neuropathy, Expert Opin Pharmacother, vol.15, issue.18, pp.2721-2752, 2014.

T. Inoue, T. Fujita, H. Kishimoto, T. Makino, T. Nakamura et al., Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules, J Bone Miner Metab, vol.27, issue.1, pp.66-75, 2009.

L. E. Vissers, G. W. Dalmeijer, J. M. Boer, M. Verschuren, W. M. Van-der-schouw et al., Intake of dietary phylloquinone and menaquinones and risk of stroke, J Am Heart Assoc, vol.2, issue.6, p.455, 2013.

P. J. Dyck, Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve, vol.11, pp.21-32, 1988.

P. J. Dyck, W. Bushek, E. M. Spring, J. L. Karnes, W. J. Litchy et al., Vibratory and cooling detection thresholds compared with other tests in diagnosing and staging diabetic neuropathy. Diabetes Care, vol.10, pp.432-472, 1987.

P. J. Dyck, K. M. Kratz, K. A. Lehman, J. L. Karnes, O. Melton-lj-3rd et al., The Rochester Diabetic Neuropathy Study: design, criteria for types of neuropathy, selection bias, and reproducibility of neuropathic tests, Neurology, vol.41, issue.6, pp.799-807, 1991.

P. J. Dyck, J. L. Karnes, P. C. O'brien, W. J. Litchy, P. A. Low et al., The Rochester Diabetic Neuropathy Study: reassessment of tests and criteria for diagnosis and staged severity, Neurology, vol.42, issue.6, pp.1164-70, 1992.

I. Feki and J. P. Lefaucheur, Correlation between nerve conduction studies and clinical scores in diabetic neuropathy, Muscle Nerve, vol.24, issue.4, pp.555-563, 2001.

M. Roustit, J. Loader, C. Deusenbery, D. Baltzis, and A. Veves, Endothelial Dysfunction as a Link Between Cardiovascular Risk Factors and Peripheral Neuropathy in Diabetes, J Clin Endocrinol Metab, vol.101, issue.9, p.27399351, 2016.

C. S. Andreassen, J. Jakobsen, and H. Andersen, Muscle weakness: a progressive late complication in diabetic distal symmetric polyneuropathy, Diabetes, vol.55, issue.3, pp.5-1237, 2006.

N. Weintrob, I. Amitay, P. Lilos, S. Shalitin, L. Lazar et al., Bedside neuropathy disability score compared to quantitative sensory testing for measurement of diabetic neuropathy in children, adolescents, and young adults with type 1 diabetes, J Diabetes Complications, vol.21, issue.1, pp.13-22, 2007.

P. J. Dyck, W. R. Sherman, L. M. Hallcher, F. J. Service, P. C. O'brien et al., Human diabetic endoneurial sorbitol, fructose, and myo-inositol related to sural nerve morphometry, Ann Neurol, vol.8, issue.6, pp.590-596, 1980.

P. J. Dyck, J. L. Karnes, J. Daube, P. O'brien, and F. J. Service, Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy, Brain, vol.108, pp.861-80, 1985.

P. J. Dyck, K. M. Kratz, J. L. Karnes, W. J. Litchy, R. Klein et al., The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study, Neurology, vol.43, issue.4, pp.817-841, 1993.